(Press-News.org) SAN FRANCISCO, CA—June 2, 2011—Scientists at the Gladstone Institutes have identified a drug candidate that diminishes the effects of both Alzheimer's disease and Huntington's disease in animal models, offering new hope for patients who currently lack any medications to halt the progression of these two debilitating illnesses.
Gladstone Investigator Paul Muchowski, PhD, has identified a new compound called JM6 in experiments done in collaboration with an international team of researchers, and which are being published today in an online article in Cell. In laboratory tests involving mice genetically engineered to model one or the other of the two diseases, Dr. Muchowski's team found that JM6 blocks kynurenine 3-monooxygenase (KMO), an enzyme that has long been speculated to play a role in neurodegenerative diseases.
In mice modeling Alzheimer's disease, the novel compound prevented memory deficits and the loss of synaptic connections between brain cells—both of which are key features of the human disease. In mice modeling Huntington's disease, JM6 prevented brain inflammation and the loss of synaptic connections between brain cells, while also extending lifespan.
The need for a therapeutic breakthrough for diseases that degrade the brain over time is great. Alzheimer's disease—the most common form of dementia—afflicts an estimated 5.4 million people in the United States alone, at an annual cost of $183 billion, according to the Alzheimer's Association. Without a therapeutic breakthrough, the number of Americans with Alzheimer's disease is expected to double by 2050, as a new case will develop every 33 seconds. Huntington's disease, meanwhile, is the most common inherited neurodegenerative brain disorder, diminishing the ability of some 30,000 Americans to walk, talk and reason.
"This discovery has significant implications for two devastating diseases and suggests that the KMO enzyme is a good protein for us to target with medications in diverse neurodegenerative disorders," said Lennart Mucke, MD, who oversees all neurological research at Gladstone and who won the prestigious Potamkin Prize last year for developing experimental strategies to make the brain more resistant to Alzheimer's. "With any luck, Dr. Muchowski and his colleagues could begin testing this drug in patients within the next two years."
Remarkably, JM6 does not penetrate into the brain, but works by inhibiting KMO in the blood. The blood cells then send a protective signal to the brain, to stabilize brain-cell function and prevent neurodegeneration. The fact that the compound does not pass the so-called blood-brain barrier will facilitate testing in patients, as JM6's potential impact could be confirmed with a simple blood test.
JM6 was named for Dr. Muchowski's father, Dr. Joseph Muchowski, Ph.D., a retired medicinal chemist who helped his son devise the novel KMO inhibitor. The study was carried out in collaboration with the laboratories of Dr. Robert Schwarcz, a University of Maryland School of Medicine professor who pioneered studies linking KMO and metabolically related enzymes to nerve-cell loss, and Professor Eliezer Masliah at the University of California, San Diego, an expert in neuropathology.
These findings are further bolstered by research also being published online today in Current Biology. Led by Flaviano Giorgini, PhD, of the University of Leicester—and a former postdoc of Dr. Muchowski's—the other study provides compelling genetic and pharmacological evidence of KMO's importance in fruit flies genetically modified to mimic Huntington's disease.
"In a world where there is such vacuum of hope about Huntington's disease, I am thrilled that someone of Dr. Muchowski's caliber has suggested the possibility of imminent clinical trials," said Charles Sabine, a former NBC correspondent who watched Huntington's disease kill his father. Both Mr. Sabine and his brother currently have Huntington's. "I believe that families with Huntington's disease should jump at the opportunity of being involved in those trials."
Gladstone, together with the University of Maryland School of Medicine, is currently considering a variety of ways to get JM6 into Phase 1 safety trials in humans—hopefully sometime in 2013—including the spinout of a venture-capital-backed startup or collaboration with a large pharmaceutical company. Gladstone also has a grant application pending with the National Institute of Neurological Disorders and Stroke to help fund safety tests required for initiating human trials. Gladstone, the National Institutes of Health and the Taube-Koret Center for Huntington's Disease Research at Gladstone all provided funding for this study.
Dr. Paul Muchowski, an associate investigator at Gladstone, specializes in neurodegenerative diseases. He is also an associate professor in the Departments of Biochemistry and Biophysics, and Neurology, at the University of California, San Francisco (UCSF).
###
About the Gladstone Institutes
Gladstone is an independent and nonprofit biomedical-research organization dedicated to accelerating the pace of scientific discovery and biomedical innovation, to prevent illness and cure patients suffering from cardiovascular disease, neurological diseases, or viral infections. Gladstone is affiliated with UCSF.
END
Levels of C-reactive protein (CRP) are increased in response to acute inflammation, infection and tissue damage. There are also reports that CRP levels are elevated because of cancer. New research published in BioMed Central's open access journal Breast Cancer Research shows that elevated CRP levels are predictive of a poor prognosis for breast cancer sufferers.
C-reactive protein is produced by the liver, in response to infection or injury, when stimulated by the cytokine IL-6. Tumor sites are often associated with inflammation and this inflammation contributes to tumor ...
Researchers at King's College London have identified a way of eliminating leukaemic stem cells, which could lead to new treatments that may enable complete remission for leukaemia patients. An early study in mice has shown that leukaemic stem cells can be abolished by suppressing two proteins found in the body.
Leukaemic stem cells sustain the disease and are likely to be responsible for relapse, so elimination of these cells is believed to be key for achieving complete remission. These encouraging findings highlight the two proteins as potential therapeutic targets ...
Students overall performed better – and educationally disadvantaged students generally made even greater strides than everyone else – in an introductory biology course at a university where recent budget woes doubled class sizes for the course, cut lab times and reduced the number of graduate teaching assistants.
The keys to success are instructors who guide learning rather than lecture, and who structure courses so students are more likely to come to class having read assignments and where they undergo intensive practice to develop critical thinking and problem solving ...
Until a decade, it was believed that differences between people were due solely to the existence of genetic changes, which are alterations in the sequence of our genes. The discoveries made during these last ten years show that beings with the same genetics like the twins and cloned animals may have different characteristics and disease due to epigenetic changes.
Epigenetics involves chemical signatures that are added to DNA and proteins that package it, to regulate their activity. The more recognized epigenetic brand is DNA methylation, a process based on the addition ...
Mutations of DNA that lead to one base being replaced by another don't have to happen as single, independent events in humans and other eukaryotes, a group of Indiana University Bloomington biologists has learned after surveying several creatures' genomes.
And, the scientists argue, if "point mutations" can happen in twos, threes -- even nines – large evolutionary jumps are possible, especially when problems caused by a single point mutation are immediately compensated for by a second or third. The work appears in the latest issue of Current Biology.
"A similar phenomenon ...
NEW YORK — June 2, 2011 — A new study by Columbia Business School Professor Paul Ingram, Kravis Professor Business, Management and senior scholar at the Jerome A. Chazen Institute for International Business at Columbia Business School; Hayagreeva Rao, Atholl McBean Professor of Organizational Behavior and Human Resources, Stanford Graduate School of Business; and Qingyuan (Lori) Yue, Assistant Professor of Management and Organization, USC Marshall School of Business, found evidence of how firms engage in regulatory arbitrage and make decisions based on a state's regulatory ...
WASHINGTON (June 2, 2011) – New research suggests an effective recovery drink may already be in your refrigerator: lowfat chocolate milk. Grabbing lowfat chocolate milk after a tough workout helped give both trained and amateur athletes a post-exercise training advantage, according to three new studies presented at the American College of Sports Medicine and published in the Journal of Strength and Conditioning Research this month. Athletes in the studies who had a post-exercise lowfat chocolate milk– with the right mix of carbs and high-quality protein – had improved ...
Last weekend saw the return of motor racing to the streets of Monte Carlo and La Condamine for what is undoubtedly the sport's most prestigious and famous event, the F1 Monaco Grand Prix. This year, Fraser Yachts secured several trackside charter yachts for clients wishing to get close to the action as well as several other anchors within the bay.
Following hot on the heels of the Cannes Film Festival, which drew to a close last Sunday, the weekend of the Monaco Grand Prix is widely regarded as the start of the Mediterranean yacht charter season and having experienced ...
NEW YORK CITY —Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each repress the critical cell cycle regulator: cyclin D1. The drug combination also broadened the reach to include a specific subset of patients, such as those resistant due to the presence of a ras mutation in their cancer. The study was published in the June issue of Cancer Prevention Research.
"Erlotinib has been found to be most effective ...
New research into drag reduction has the potential to help industries such shipping to reduce energy use and carbon emissions.
Professor Derek Chan from the University of Melbourne's Department of Mathematics and Statistics said the research demonstrates a new way to minimise drag of fast moving projectiles in water.
A collaboration between the University of Melbourne and the King Abdulla University of Science and Technology in Saudi Arabia, the research was based on the 255 year-old Leidenfrost effect.
The Leidenfrost effect describes the phenomenon where a liquid ...
